References
- T.M. Mekhail and M. Markman, Exp. Opin. Pharmacother. 3, 755 (2002)
- S.B. Horwitz, Trends Pharmacol. Sci. 13, 134 (1992)
- M. Kavallaris, Nat. Rev. Cancer 10, 194 (2010)
- R.Z. Yusuf, Z. Duan, D.E. Lamendola, R.T. Penson, and M.V. Seiden, Curr. Cancer Drug Targets 3, 1 (2003)
- L.M. Yu, C. Peng, S.M. Starnes, R.S. Liou, and T.W. Chang, J. Immunol. 145, 3932 (1990)
- A. Kelly, S.H. Powis, L.A. Kerr, I. Mockridge, T. Elliott, J. Bastin, B. Uchanska-Ziegler, A. Ziegler, J. Trowsdale, and A. Townsend, Nature 355, 641 (1992)
- I. Abraham, K. El Sayed, Z.S. Chen, and H. Guo, Mar. Drugs 10, 2312 (2012)
- D.A. Laska, J.O. Houchins, S.E. Pratt, J. Horn, X. Xia, B.R. Hanssen, D.C. Williams, A.H. Dantzig, and T. Lindstrom, In Vitro Cell Dev. Biol. Anim. 38, 401 (2002)
- F. Zagouri, T.N. Sergentanis, D. Chrysikos, M. Filipits, and R. Bartsch, Oncology 83, 234 (2012)
- S. Murray, E. Briasoulis, H. Linardou, D. Bafaloukos, and C. Papadimitriou, Cancer Treat Rev. 38, 890 (2012)
- M. Mimeault, R. Hauke, and S.K. Batra, Clin. Pharmacol. Ther. 83, 673 (2008)
- N. Duarte, A. Varga, G. Cherepnev, R. Radics, J. Molnar, and M.J. Ferreira, Bioorg. Med. Chem. 15, 546 (2007)
- E. Roger, F. Lagarce, E. Garcion, and J.P. Benoit, Eur. J. Pharm. Sci. 40, 422 (2010)
- G. Gutierrez-Venegas, A. Contreras-Sanchez, J.A. Ventura-Arroyo, and J. Asian, Nat. Prod. Res. 16, 1009 (2014)
- F. You, J. Hu, X. Li, and Y. Li, Cancer Chemother. Pharmacol. 71, 1453 (2013)